Berubicin - CNS Pharmaceuticals
Alternative Names: Berubicin hydrochloride; Reata 744; RTA 744; WP744Latest Information Update: 09 Apr 2024
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer CNS Pharmaceuticals; WPD Pharmaceuticals
- Class Amines; Anthracyclines; Antineoplastics; Carboxylic acids; Ethers; Pyrans; Small molecules
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Glioblastoma
- Phase I/II Lymphoma
- Research Breast cancer; Lung cancer
- No development reported Ovarian cancer; Pancreatic cancer
- Discontinued Brain metastases; Neoplastic meningitis
Most Recent Events
- 05 Apr 2024 WPD Pharmaceuticals terminates a phase I/II trial for Glioblastoma (Second-line therapy or greater) in Poland (IV, Infusion) due to progress made by their licensor, CNS Pharmaceuticals, in the potentially pivotal CNS-201 trial (NCT04915404)
- 30 Dec 2023 WPD Pharmaceuticals withdraws a phase I trial in Glioma (In children, In adolescents, Second-line therapy or greater), prior to enrolment due to business decision (IV) (NCT05082493)
- 28 Dec 2023 No recent reports of development identified for preclinical development in Lymphoma in USA (IV)